Zydus Therapeutics’ New Drug Application (NDA) for Saroglitazar to treat Primary Biliary Cholangitis (PBC) granted Priority Review by the US FDA
EPICS-III trial Phase 3 results demonstrated significant biochemical response; data to be presented as a late-breaking presentation at EASL Congress 2026. ● US FDA granted Priority Review and assigned PDUFA…










